我们需要主题专业知识来选择和识别因果估计:评论“在终端事件存在的情况下对重复事件终点的估计”

IF 1.5 4区 医学 Q3 MATHEMATICAL & COMPUTATIONAL BIOLOGY Statistics in Biopharmaceutical Research Pub Date : 2023-04-03 DOI:10.1080/19466315.2022.2108138
Matias Janvin, Jessica G. Young, M. J. Stensrud
{"title":"我们需要主题专业知识来选择和识别因果估计:评论“在终端事件存在的情况下对重复事件终点的估计”","authors":"Matias Janvin, Jessica G. Young, M. J. Stensrud","doi":"10.1080/19466315.2022.2108138","DOIUrl":null,"url":null,"abstract":"Abstract We summarize what we consider to be the two main limitations of the “Estimands for Recurrent Event Endpoints in the Presence of a Terminal Event” (Schmidli et al. 2022). First, the authors did not give detailed guidance on how to choose an appropriate estimand in light of subject-matter considerations. Reasoning about the mechanism by which treatment affects different types of events is central when selecting a causal estimand, and such reasoning can be grounded in the interventionist mediation literature. Second, the article also did not discuss the crucial task of identification when the aim is to study a causal question. Thereby, the authors omit important differences in the uncertainty of the assumptions needed to target each estimand by particular statistical methods. These assumptions have crucial implications for the confidence that can be placed in a given effect estimate, and for the planning and collection of relevant variables in the study design.","PeriodicalId":51280,"journal":{"name":"Statistics in Biopharmaceutical Research","volume":null,"pages":null},"PeriodicalIF":1.5000,"publicationDate":"2023-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"We Need Subject Matter Expertise to Choose and Identify Causal Estimands: Comment on “Estimands for Recurrent Event Endpoints in the Presence of a Terminal Event”\",\"authors\":\"Matias Janvin, Jessica G. Young, M. J. Stensrud\",\"doi\":\"10.1080/19466315.2022.2108138\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Abstract We summarize what we consider to be the two main limitations of the “Estimands for Recurrent Event Endpoints in the Presence of a Terminal Event” (Schmidli et al. 2022). First, the authors did not give detailed guidance on how to choose an appropriate estimand in light of subject-matter considerations. Reasoning about the mechanism by which treatment affects different types of events is central when selecting a causal estimand, and such reasoning can be grounded in the interventionist mediation literature. Second, the article also did not discuss the crucial task of identification when the aim is to study a causal question. Thereby, the authors omit important differences in the uncertainty of the assumptions needed to target each estimand by particular statistical methods. These assumptions have crucial implications for the confidence that can be placed in a given effect estimate, and for the planning and collection of relevant variables in the study design.\",\"PeriodicalId\":51280,\"journal\":{\"name\":\"Statistics in Biopharmaceutical Research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2023-04-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Statistics in Biopharmaceutical Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/19466315.2022.2108138\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MATHEMATICAL & COMPUTATIONAL BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Statistics in Biopharmaceutical Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/19466315.2022.2108138","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MATHEMATICAL & COMPUTATIONAL BIOLOGY","Score":null,"Total":0}
引用次数: 1

摘要

摘要我们总结了我们认为的“在终端事件存在的情况下对重复事件终点的估计”的两个主要限制(Schmidli et al. 2022)。首先,作者没有就如何根据主题事项考虑选择适当的估计给出详细的指导。在选择因果估计时,关于治疗影响不同类型事件的机制的推理是核心,这种推理可以在干预主义调解文献中建立基础。其次,本文也没有讨论识别的关键任务,当目的是研究一个因果问题。因此,作者通过特定的统计方法忽略了针对每个估计所需的假设不确定性中的重要差异。这些假设对于给定效果估计的置信度以及研究设计中相关变量的规划和收集具有至关重要的意义。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
We Need Subject Matter Expertise to Choose and Identify Causal Estimands: Comment on “Estimands for Recurrent Event Endpoints in the Presence of a Terminal Event”
Abstract We summarize what we consider to be the two main limitations of the “Estimands for Recurrent Event Endpoints in the Presence of a Terminal Event” (Schmidli et al. 2022). First, the authors did not give detailed guidance on how to choose an appropriate estimand in light of subject-matter considerations. Reasoning about the mechanism by which treatment affects different types of events is central when selecting a causal estimand, and such reasoning can be grounded in the interventionist mediation literature. Second, the article also did not discuss the crucial task of identification when the aim is to study a causal question. Thereby, the authors omit important differences in the uncertainty of the assumptions needed to target each estimand by particular statistical methods. These assumptions have crucial implications for the confidence that can be placed in a given effect estimate, and for the planning and collection of relevant variables in the study design.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Statistics in Biopharmaceutical Research
Statistics in Biopharmaceutical Research MATHEMATICAL & COMPUTATIONAL BIOLOGY-STATISTICS & PROBABILITY
CiteScore
3.90
自引率
16.70%
发文量
56
期刊介绍: Statistics in Biopharmaceutical Research ( SBR), publishes articles that focus on the needs of researchers and applied statisticians in biopharmaceutical industries; academic biostatisticians from schools of medicine, veterinary medicine, public health, and pharmacy; statisticians and quantitative analysts working in regulatory agencies (e.g., U.S. Food and Drug Administration and its counterpart in other countries); statisticians with an interest in adopting methodology presented in this journal to their own fields; and nonstatisticians with an interest in applying statistical methods to biopharmaceutical problems. Statistics in Biopharmaceutical Research accepts papers that discuss appropriate statistical methodology and information regarding the use of statistics in all phases of research, development, and practice in the pharmaceutical, biopharmaceutical, device, and diagnostics industries. Articles should focus on the development of novel statistical methods, novel applications of current methods, or the innovative application of statistical principles that can be used by statistical practitioners in these disciplines. Areas of application may include statistical methods for drug discovery, including papers that address issues of multiplicity, sequential trials, adaptive designs, etc.; preclinical and clinical studies; genomics and proteomics; bioassay; biomarkers and surrogate markers; models and analyses of drug history, including pharmacoeconomics, product life cycle, detection of adverse events in clinical studies, and postmarketing risk assessment; regulatory guidelines, including issues of standardization of terminology (e.g., CDISC), tolerance and specification limits related to pharmaceutical practice, and novel methods of drug approval; and detection of adverse events in clinical and toxicological studies. Tutorial articles also are welcome. Articles should include demonstrable evidence of the usefulness of this methodology (presumably by means of an application). The Editorial Board of SBR intends to ensure that the journal continually provides important, useful, and timely information. To accomplish this, the board strives to attract outstanding articles by seeing that each submission receives a careful, thorough, and prompt review. Authors can choose to publish gold open access in this journal.
期刊最新文献
A Basket Trial Design Based on Power Priors Remembering Gregory Campbell (1949-2023): An Accomplished Leader, Mentor, and Biostatistical Innovator Combining Recurrent and Terminal Events Into a Composite Endpoint May Be Problematic Simultaneous Confidence Intervals for Signal Detection and Ascertaining Precision of Adverse Event Rates in Clinical Trials Bayesian shrinkage estimation of credible subgroups for count data with excess zeros
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1